Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 42

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 42
---
.” and FutureTech’s common stock is expected to list on Nasdaq under the ticker symbol “LBIO.”

Merger Consideration

The aggregate consideration (the “Merger Consideration”) to be paid to the holders of Longevity common stock, par value $0.0001 per share (the “Longevity Common Stock”), at the Closing will consist of a number of shares of FutureTech common stock, par value $0.0001 (“Common Stock”) equal to (a) (i) $100,000,000 minus (ii) the value of each outstanding option (whether vested or unvested)s to purchase Longevity Common Stock that is converted into a new FutureTech option in accordance with the Merger Agreement, divided by (b) $10.00.

Merger Effective Time

On the terms and subject to the conditions set forth in the Merger Agreement, at the effective time of the Merger (the “Merger Effective Time”), by virtue of the Merger:

(a) each share of Longevity Common Stock (including shares issued in connection with the Target Acquisitions and the conversion of certain Longevity indebtedness) outstanding immediately prior to the Merger Effective Time (other than dissenting shares) will be converted into the right to receive a number of shares of FutureTech Common Stock equal to: (i) the aggregate Merger Consideration divided by (ii) the number of outstanding shares of Longevity Common Stock (including each share of Longevity Common Stock to be issued in connection with the Target Acquisitions and upon conversion of the Longevity indebtedness); and (b) each outstanding Longevity vested option to purchase Longevity Common Stock shall be converted into a FutureTech option to acquire the number of shares of FutureTech Common Stock calculated in accordance with the Merger Agreement; and

(b) each share of FutureTech Common Stock issued and outstanding immediately prior to the Merger Effective Time with respect to which a FutureTech stockholder has validly exercised its redemption rights (collectively, the “Redemption Shares”) will not be converted into and become a share of FutureTech Common Stock, and instead will at the Merger Effective Time be converted into the right to receive from FutureTech, in cash, an amount per share calculated in accordance with such stockholder’s redemption rights.

| 4 |

For further details, see the section entitled “ Proposal No.1 — The Business Combination Proposal.” Closing Conditions The consummation of the Business Combination is subject to customary closing conditions for transactions involving special purpose acquisition